Cancer - Sparx Biotech

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT06259552

A Phase 1, Open-label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of an anti-LIBRB2 / PD-L1 bispecific antibody SPX- 303 in Patients with Solid Tumors

Drug

SPX-303

Condition

Patients with Solid Tumors